Pradaxa: safety update owing to risk of serious haemorrhage

The MHRA has issued updated safety advice for the anticoagulant dabigatran (Pradaxa).

Concomitant use of antiplatelet agents with dabigatran increases the risk of major bleeding approximately three-fold | SCIENCE PHOTO LIBRARY
Concomitant use of antiplatelet agents with dabigatran increases the risk of major bleeding approximately three-fold | SCIENCE PHOTO LIBRARY

Use of dabigatran with dronedarone or alongside other anticoagulants is contraindicated. The only exceptions to this advice are when switching anticoagulant therapy to or from dabigatran, or using unfractionated heparin for maintenance of catheter patency.

Further contraindications

The agency reminds healthcare professionals that dabigatran is also contraindicated in clinical conditions where the patient is at significant risk of major bleeding. These include:

  • current or recent gastrointestinal ulceration;
  • malignant neoplasms;
  • recent brain or spinal injury;
  • recent brain, spinal or ophthalmic surgery;
  • recent intracranial haemorrhage;
  • oesophageal varices;
  • arteriovenous malformations;
  • vascular aneurysms;
  • major intraspinal or intracerebral vascular abnormalities.

Clinicians should carefully assess the benefits and risks of starting dabigatran in patients who may have other conditions that increase the risk of bleeding.

Assess for kidney dysfunction

Renal function should be assessed in all patients before starting dabigatran.

View Pradaxa drug record

Further information: Boehringer Ingelheim Ltd

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

NICE recommends dabigatran as an option in thromboembolism

NICE recommends dabigatran as an option in thromboembolism

NICE has recommended that dabigatran etexilate (Pradaxa)...

Pradaxa now indicated for DVT and PE

Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment...

NICE approves dabigatran in atrial fibrillation

NICE approves dabigatran in atrial fibrillation

Dabigatran etexilate (Pradaxa) can now be prescribed...

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa (dabigatran) is now licensed for the prevention...

New oral anticoagulant approved

New oral anticoagulant approved

Apixaban is set to launch in the UK after being approved...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases